Roberto Ferrara, Researcher in Thoracic Oncology and Molecular Immunology at IRCCS University San Raffaele, shared on X:
“Unclear whether mono arm underperformed and the exact role of PD-L1 in Persee.
Median PFS mono ICI in PD-L1 >90: 10-15 months vs 7 months in Persee in all high PD-L1 subcategories.
OS>50 months with chemo-ICI unrealistic.
Need more follow up”
You may also be interested in:
Nabil Ismaili: PERSEE Trial Settles the PD-L1-High NSCLC Debate?
